N Ferrara

Summary

Affiliation: Genentech Inc
Country: USA

Publications

  1. ncbi Angiogenesis as a therapeutic target
    Napoleone Ferrara
    Genentech, 1 DNA Way, South San Francisco, California 94080, USA
    Nature 438:967-74. 2005
  2. doi Refractoriness to antivascular endothelial growth factor treatment: role of myeloid cells
    Farbod Shojaei
    Genentech, Inc, South San Francisco, California 94080, USA
    Cancer Res 68:5501-4. 2008
  3. ncbi Role of vascular endothelial growth factor in regulation of physiological angiogenesis
    N Ferrara
    Department of Molecular Oncology, Genentech, Inc, South San Francisco, CA 94080, USA
    Am J Physiol Cell Physiol 280:C1358-66. 2001
  4. ncbi Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
    Napoleone Ferrara
    Department of Molecular Oncology, Genentech, Inc, 1 DNA Way, South San Francisco, California 94080, USA
    Nat Rev Drug Discov 3:391-400. 2004
  5. ncbi Role of vascular endothelial growth factor in the regulation of angiogenesis
    N Ferrara
    Department of Cardiovascular Research, Genentech, Inc, South San Francisco, California 94080, USA
    Kidney Int 56:794-814. 1999
  6. ncbi Molecular and biological properties of vascular endothelial growth factor
    N Ferrara
    Department of Cardiovascular Research, Genentech Inc, South San Francisco, CA 94080, USA
    J Mol Med (Berl) 77:527-43. 1999
  7. ncbi EG-VEGF and Bv8: a novel family of tissue-restricted angiogenic factors
    Napoleone Ferrara
    Department of Molecular Oncology, Genentech Inc, South San Francisco, CA 94080, USA
    Biochim Biophys Acta 1654:69-78. 2004
  8. ncbi Clinical applications of angiogenic growth factors and their inhibitors
    N Ferrara
    Department of Molecular Oncology Genentech DNA Way South San Francisco, California 94080, USA
    Nat Med 5:1359-64. 1999
  9. ncbi The biology of VEGF and its receptors
    Napoleone Ferrara
    Department of Molecular Oncology, Genentech, Inc, 1 DNA Way, South San Francisco, California 94080, USA
    Nat Med 9:669-76. 2003
  10. ncbi Endocrine gland vascular endothelial growth factor (EG-VEGF) and the hypothesis of tissue-specific regulation of angiogenesis
    Napoleone Ferrara
    Department of Molecular Oncology, Genentech Inc, South San Francisco, CA 94080, USA
    Endocr Res 28:763-4. 2002

Research Grants

Detail Information

Publications96

  1. ncbi Angiogenesis as a therapeutic target
    Napoleone Ferrara
    Genentech, 1 DNA Way, South San Francisco, California 94080, USA
    Nature 438:967-74. 2005
    ..Therapeutic angiogenesis (promoting new vessel growth to treat ischaemic disorders) is an exciting frontier of cardiovascular medicine, but further understanding of the mechanisms of vascular morphogenesis is needed first...
  2. doi Refractoriness to antivascular endothelial growth factor treatment: role of myeloid cells
    Farbod Shojaei
    Genentech, Inc, South San Francisco, California 94080, USA
    Cancer Res 68:5501-4. 2008
    ..Thus, G-CSF may promote tumor angiogenesis through a Bv8-dependent pathway that bypasses VEGF and renders tumors refractory to anti-VEGF therapy...
  3. ncbi Role of vascular endothelial growth factor in regulation of physiological angiogenesis
    N Ferrara
    Department of Molecular Oncology, Genentech, Inc, South San Francisco, CA 94080, USA
    Am J Physiol Cell Physiol 280:C1358-66. 2001
    ..Substantial evidence also implicates VEGF as an angiogenic mediator in tumors and intraocular neovascular syndromes, and numerous clinical trials are presently testing the hypothesis that inhibition of VEGF may have therapeutic value...
  4. ncbi Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
    Napoleone Ferrara
    Department of Molecular Oncology, Genentech, Inc, 1 DNA Way, South San Francisco, California 94080, USA
    Nat Rev Drug Discov 3:391-400. 2004
  5. ncbi Role of vascular endothelial growth factor in the regulation of angiogenesis
    N Ferrara
    Department of Cardiovascular Research, Genentech, Inc, South San Francisco, California 94080, USA
    Kidney Int 56:794-814. 1999
    ..Currently, both therapeutic angiogenesis using recombinant VEGF or VEGF gene transfer and inhibition of VEGF-mediated pathological angiogenesis are being pursued clinically...
  6. ncbi Molecular and biological properties of vascular endothelial growth factor
    N Ferrara
    Department of Cardiovascular Research, Genentech Inc, South San Francisco, CA 94080, USA
    J Mol Med (Berl) 77:527-43. 1999
    ..Currently, both therapeutic angiogenesis using recombinant VEGF or VEGF gene transfer and inhibition of VEGF-mediated pathological angiogenesis are being pursued...
  7. ncbi EG-VEGF and Bv8: a novel family of tissue-restricted angiogenic factors
    Napoleone Ferrara
    Department of Molecular Oncology, Genentech Inc, South San Francisco, CA 94080, USA
    Biochim Biophys Acta 1654:69-78. 2004
    ..Bv8 expression is mainly restricted to the testis. The identification of these tissue-selective angiogenic factors raises the possibility that other secreted molecules with selectivity for the endothelium of other organs exist...
  8. ncbi Clinical applications of angiogenic growth factors and their inhibitors
    N Ferrara
    Department of Molecular Oncology Genentech DNA Way South San Francisco, California 94080, USA
    Nat Med 5:1359-64. 1999
    ..These concepts are being tested now in clinical trials...
  9. ncbi The biology of VEGF and its receptors
    Napoleone Ferrara
    Department of Molecular Oncology, Genentech, Inc, 1 DNA Way, South San Francisco, California 94080, USA
    Nat Med 9:669-76. 2003
    ..VEGF inhibition is also being tested as a strategy for the prevention of angiogenesis, vascular leakage and visual loss in age-related macular degeneration...
  10. ncbi Endocrine gland vascular endothelial growth factor (EG-VEGF) and the hypothesis of tissue-specific regulation of angiogenesis
    Napoleone Ferrara
    Department of Molecular Oncology, Genentech Inc, South San Francisco, CA 94080, USA
    Endocr Res 28:763-4. 2002
  11. ncbi VEGF: an update on biological and therapeutic aspects
    N Ferrara
    Department of Molecular Oncology, Genentech Inc, 1 DNA Way, South San Francisco, CA 94080, USA
    Curr Opin Biotechnol 11:617-24. 2000
    ..Substantial evidence also implicates VEGF in tumors and intraocular neovascular syndromes. Currently, several clinical trials are ongoing to test the hypothesis that the inhibition of VEGF activity may be beneficial for these conditions...
  12. ncbi VEGF and the quest for tumour angiogenesis factors
    Napoleone Ferrara
    Department of Molecular Oncology, Genentech, Inc, 1 DNA Way, South San Francisco, California 94080, USA
    Nat Rev Cancer 2:795-803. 2002
    ..How did this field begin, and how have we arrived at our present understanding of the role of VEGF in tumour progression...
  13. ncbi Vascular endothelial growth factor: basic science and clinical progress
    Napoleone Ferrara
    Department of Molecular Oncology, Genentech, Inc, 1 DNA Way, South San Francisco, CA 94080, USA
    Endocr Rev 25:581-611. 2004
    ..Furthermore, VEGF is implicated in intraocular neovascularization associated with diabetic retinopathy and age-related macular degeneration...
  14. ncbi Vascular endothelial growth factor as a target for anticancer therapy
    Napoleone Ferrara
    Genentech, Inc, South San Francisco, California 94080, USA
    Oncologist 9:2-10. 2004
    ..Of these, bevacizumab, a humanized monoclonal antibody directed at VEGF, is the most advanced in clinical development and has shown promising results in clinical trials...
  15. ncbi Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy
    Napoleone Ferrara
    Department of Molecular Oncology, Genentech, Inc, 1 DNA Way, South San Francisco, CA 94080, USA
    Biochem Biophys Res Commun 333:328-35. 2005
    ..Furthermore, VEGF is implicated in intraocular neovascularization associated with diabetic retinopathy and age-related macular degeneration...
  16. doi Role of myeloid cells in vascular endothelial growth factor-independent tumor angiogenesis
    Napoleone Ferrara
    Genentech, Inc, 1 DNA Way, South San Francisco, California, USA
    Curr Opin Hematol 17:219-24. 2010
    ..This review describes recent findings on the role of myeloid cells in refractoriness or/and acquired resistance to such therapies...
  17. pmc Binding to the extracellular matrix and proteolytic processing: two key mechanisms regulating vascular endothelial growth factor action
    Napoleone Ferrara
    Genentech, Inc, South San Francisco, CA 94080, USA
    Mol Biol Cell 21:687-90. 2010
    ..This retrospective article examines the early studies and also emphasizes the subsequent progress in our understanding of these processes in health and disease...
  18. doi VEGF-A: a critical regulator of blood vessel growth
    Napoleone Ferrara
    Genentech, Inc, San Francisco, CA 94080, USA
    Eur Cytokine Netw 20:158-63. 2009
    ..This article examines the molecular and biological characteristics of VEGF and also discusses preclinical and clinical studies with VEGF inhibitors and the lessons learned from these studies...
  19. doi Pathways mediating VEGF-independent tumor angiogenesis
    Napoleone Ferrara
    Genentech, Inc, 1 DNA Way, South San Francisco, CA 94080, USA
    Cytokine Growth Factor Rev 21:21-6. 2010
    ..The present review examines the role of tumor- as well as stromal cell-derived pathways involved in tumor growth and in refractoriness to anti-VEGF therapies...
  20. ncbi The role of vascular endothelial growth factor in angiogenesis
    N Ferrara
    Department of Molecular Oncology, Genentech, Inc, South San Francisco, Calif 94080, USA
    Acta Haematol 106:148-56. 2001
    ..Substantial evidence also implicates VEGF in tumors and intraocular neovascular syndromes. Currently, several clinical trials are ongoing to test the hypothesis that inhibition of VEGF activity may be beneficial for these conditions...
  21. doi Vascular endothelial growth factor
    Napoleone Ferrara
    Genentech Inc, 1 DNA Way, South San Francisco, CA 94080, USA
    Arterioscler Thromb Vasc Biol 29:789-91. 2009
    ..This brief review provides a historic account of the challenges associated with the discovery of VEGF and the early steps in elucidating the role of this molecule in the regulation of angiogenesis...
  22. ncbi Targeting VEGF-A to treat cancer and age-related macular degeneration
    Napoleone Ferrara
    Genentech, Inc, South San Francisco, California 94080, USA
    Annu Rev Med 58:491-504. 2007
    ..S. Food and Drug Administration for the treatment of cancer and the neovascular form of age-related macular degeneration. This review summarizes the basic biology of VEGF-A and illustrates the clinical progress in targeting this molecule...
  23. ncbi Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration
    Napoleone Ferrara
    Genentech, Inc, 1 DNA Way, South San Francisco, CA 94080, USA
    Retina 26:859-70. 2006
    ..Among these, ranibizumab is a high affinity recombinant Fab that neutralizes all isoforms of VEGF-A. The article briefly reviews the biology of VEGF and then focuses on the path that led to clinical development of ranibizumab...
  24. ncbi The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency
    B A Keyt
    Department of Cardiovascular Research, Genentech, Inc, South San Francisco, California 94080, USA
    J Biol Chem 271:7788-95. 1996
    ..The present findings indicate that removal of the carboxyl-terminal domain, whether it is due to alternative splicing of mRNA or to proteolysis, is associated with a significant loss in bioactivity...
  25. ncbi VEGF is required for growth and survival in neonatal mice
    H P Gerber
    Departments of Cardiovascular Research and Pathology, Genentech, Inc, South San Francisco, CA 94080, USA
    Development 126:1149-59. 1999
    ..Thus, VEGF is essential for growth and survival in early postnatal life. However, in the fully developed animal, VEGF is likely to be involved primarily in active angiogenesis processes such as corpus luteum development...
  26. ncbi Identification of an angiogenic mitogen selective for endocrine gland endothelium
    J LeCouter
    Department of Molecular Oncology, Genentech Inc, South San Francisco, CA 94080, USA
    Nature 412:877-84. 2001
    ..EG-VEGF is an example of a class of highly specific mitogens that act to regulate proliferation and differentiation of the vascular endothelium in a tissue-specific manner...
  27. ncbi Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR
    J E Park
    Genentech, Inc, South San Francisco, California 94080
    J Biol Chem 269:25646-54. 1994
    ..Purified PIGF isoforms had little or no direct mitogenic or permeability-enhancing activity. However, they were able to significantly potentiate the action of low concentrations of VEGF in vitro and, more strikingly, in vivo...
  28. ncbi Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants
    H Gille
    Department of Molecular Oncology, Genentech, Inc, South San Francisco, California 94080, USA
    J Biol Chem 276:3222-30. 2001
    ..We also demonstrate that KDR, but not Flt-1, stimulation is responsible for the induction of vascular permeability by VEGF...
  29. ncbi Identification of vascular endothelial growth factor determinants for binding KDR and FLT-1 receptors. Generation of receptor-selective VEGF variants by site-directed mutagenesis
    B A Keyt
    Department of Cardiovascular Research, Genentech, Inc, South San Francisco, California 94080, USA
    J Biol Chem 271:5638-46. 1996
    ..Furthermore, this mutational analysis implicates KDR, but not FLT-1, in VEGF induction of endothelial cell proliferation...
  30. ncbi Vascular endothelial growth factor is essential for corpus luteum angiogenesis
    N Ferrara
    Department of Cardiovascular Research, Genentech Inc, South San Francisco, California 94080, USA
    Nat Med 4:336-40. 1998
    ..Furthermore, they have implications for the control of fertility and the treatment of ovarian disorders characterized by hypervascularity and hyperplasia...
  31. ncbi Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration
    J Mordenti
    Department of Experimental Therapeutics, Genentech, Inc, Souty San Francisco, California 94080, USA
    Toxicol Pathol 27:536-44. 1999
    ..The differences in pharmacokinetics and tissue distribution that are noted between the full-length and Fab antibodies in this study identify potential therapeutic approaches that may be exploited in specific disease conditions...
  32. ncbi Mapping the charged residues in the second immunoglobulin-like domain of the vascular endothelial growth factor/placenta growth factor receptor Flt-1 required for binding and structural stability
    T Davis-Smyth
    Departments of Cardiovascular Research, Genentech, Inc, South San Francisco, California 94080, USA
    J Biol Chem 273:3216-22. 1998
    ..In addition, some residues in domain 3 contribute to binding (Asp231) or provide for additional discrimination between ligands (Arg280-Asp283)...
  33. ncbi Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene
    N Ferrara
    Department of Cardiovascular Research, Genentech Inc, South San Francisco, California 94080, USA
    Nature 380:439-42. 1996
    ..Angiogenesis and blood-island formation were impaired, resulting in several developmental anomalies. Furthermore, VEGF-null embryonic stem cells exhibit a dramatically reduced ability to form tumours in nude mice...
  34. pmc A repressor sequence in the juxtamembrane domain of Flt-1 (VEGFR-1) constitutively inhibits vascular endothelial growth factor-dependent phosphatidylinositol 3'-kinase activation and endothelial cell migration
    H Gille
    Department of Molecular Oncology, Genentech, Inc, 1 DNA Way, South San Francisco, CA 94080, USA
    EMBO J 19:4064-73. 2000
    ..These results define a novel functional domain that serves to repress Flt-1 activity in endothelial cells...
  35. ncbi Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation
    H P Gerber
    Department of Cardiovascular Research, Genentech, Inc, South San Francisco, California 94080, USA
    J Biol Chem 273:30336-43. 1998
    ..Inhibition of apoptosis may represent a major aspect of the regulatory activity of VEGF on the vascular endothelium...
  36. ncbi Dobutamine stress cine-MRI of cardiac function in the hearts of adult cardiomyocyte-specific VEGF knockout mice
    S P Williams
    Genentech, Inc, 1 DNA Way 72A, South San Francisco, CA 94080, USA
    J Magn Reson Imaging 14:374-82. 2001
    ..A prolonged high-dose dobutamine challenge was monitored by MRI. A maximal response was sustained for 90 minutes, suggesting that it did not depend on endogenous glycogen stores...
  37. pmc VEGF antagonism reduces edema formation and tissue damage after ischemia/reperfusion injury in the mouse brain
    N van Bruggen
    Department of Neuroscience, Genentech Inc, South San Francisco, California 94080, USA
    J Clin Invest 104:1613-20. 1999
    ..These results demonstrate that antagonism of VEGF reduces ischemia/reperfusion-related brain edema and injury, implicating VEGF in the pathogenesis of stroke and related disorders...
  38. ncbi Efficacy and concentration-response of murine anti-VEGF monoclonal antibody in tumor-bearing mice and extrapolation to humans
    J Mordenti
    Experimental Therapeutics, Genentech, Inc, South San Francisco, California 94080, USA
    Toxicol Pathol 27:14-21. 1999
    ....
  39. ncbi Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovarian cancer cells
    Y L Hu
    Center for Reproductive Sciences, University of California, San Francisco, USA
    J Natl Cancer Inst 93:762-8. 2001
    ..However, this LPA response is not evident in normal ovarian surface epithelial cells. Our data suggest that Edg4, but not Edg2, plays a role in LPA stimulation of ovarian tumor growth...
  40. ncbi Vascular endothelial growth factor is a secreted angiogenic mitogen
    D W Leung
    Department of Molecular Biology, Genetech, South San Francisco, CA 94080
    Science 246:1306-9. 1989
    ..Human 293 cells transfected with an expression vector containing a bovine or human VEGF cDNA insert secrete an endothelial cell mitogen that behaves like native VEGF...
  41. ncbi Differential transcriptional regulation of the two vascular endothelial growth factor receptor genes. Flt-1, but not Flk-1/KDR, is up-regulated by hypoxia
    H P Gerber
    Department of Cardiovascular Research, Genentech, Inc, South San Francisco, California 94080, USA
    J Biol Chem 272:23659-67. 1997
    ..These findings indicate that, unlike the KDR/Flk-1 gene, the Flt-1 receptor gene is directly up-regulated by hypoxia via a hypoxia-inducible enhancer element located at positions -976 to -937 of the Flt-1 promoter...
  42. ncbi The role of EG-VEGF in the regulation of angiogenesis in endocrine glands
    J LeCouter
    Department of Molecular Oncology, Genentech, Inc, South San Francisco, California 94080, USA
    Cold Spring Harb Symp Quant Biol 67:217-21. 2002
  43. pmc Hepatocyte growth factor enhances vascular endothelial growth factor-induced angiogenesis in vitro and in vivo
    X Xin
    Department of Cardiovascular Research, Genentech Inc, South San Francisco, CA 94080, USA
    Am J Pathol 158:1111-20. 2001
    ..We suggest that combination therapy using HGF and VEGF co-administration may provide a more effective strategy to achieve therapeutic angiogenesis...
  44. ncbi The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA
    K A Houck
    Department of Molecular Biology, Genetech, Inc, South San Francisco, California 94080
    Mol Endocrinol 5:1806-14. 1991
    ..Thus, alternative splicing of VEGF RNA can produce four polypeptides with strikingly different secretion patterns, which suggests multiple physiological roles for this family of proteins...
  45. ncbi Induction of vascular endothelial growth factor by insulin-like growth factor 1 in colorectal carcinoma
    R S Warren
    Department of Surgery, University of California School of Medicine, San Francisco, California 94143, USA
    J Biol Chem 271:29483-8. 1996
    ..Thus, in addition to its direct, growth stimulatory effect on transformed cells, IGF-I induces the expression of VEGF which can promote the progression of cancer by regulating the development of new blood vessels...
  46. ncbi Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells
    N Ferrara
    Department of Pharmacological Sciences, Genentech Inc, South San Francisco, CA 94080
    Biochem Biophys Res Commun 161:851-8. 1989
    ..Microsequencing reveals a unique N-terminal amino acid sequence. On the basis of its apparent target cell selectivity, we propose to name this factor vascular endothelial growth factor (VEGF)...
  47. ncbi Angiogenesis and bone growth
    H P Gerber
    Department of Molecular Oncology, Genentech, Inc, South San Francisco, CA 94080, USA
    Trends Cardiovasc Med 10:223-8. 2000
    ..The fundamental importance of chondrocytes in the growth, development and repair of the skeleton has led to intense investigation of the mechanisms that regulate chondrocyte maturation and apoptosis...
  48. doi Developmental and pathological angiogenesis
    Alicia S Chung
    Genentech, Inc, South San Francisco, California 94080, USA
    Annu Rev Cell Dev Biol 27:563-84. 2011
    ..We also discuss current knowledge of physiological angiogenic processes as well as their disruptions in pathological processes, particularly tumorigenesis...
  49. pmc Vascular endothelial growth factor expression in the retinal pigment epithelium is essential for choriocapillaris development and visual function
    Alexander G Marneros
    Department of Cell Biology, Harvard Medical School, 188 Longwood Ave, Boston, MA 02115, USA
    Am J Pathol 167:1451-9. 2005
    ..Thus, hypoxia-inducible factor-1alpha-independent expression of VEGF is essential for choroid development...
  50. ncbi Angiogenic inhibitors: a new therapeutic strategy in oncology
    Giampietro Gasparini
    Division of Medical Oncology, San Filippo Neri Hospital, Via G Martinotti, 20 00135 Rome, Italy
    Nat Clin Pract Oncol 2:562-77. 2005
    ....
  51. ncbi Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF
    Wei Ching Liang
    Department of Protein Engineering, Genentech Inc, South San Francisco, CA 94080, USA
    J Biol Chem 281:951-61. 2006
    ..Thus, the functional contribution of stromal VEGF varies greatly among tumors, and systemic blockade of both tumor and stroma-derived VEGF is sufficient for inhibiting the growth of tumor xenografts...
  52. ncbi VEGF as a therapeutic target in cancer
    Napoleone Ferrara
    Genentech Inc, San Francisco, Calif 94080, USA
    Oncology 69:11-6. 2005
    ..The best-studied and most advanced approach to VEGF inhibition is the humanized monoclonal antibody bevacizumab (Avastin), which is the only anti-angiogenic agent approved for treatment of cancer...
  53. ncbi Tumor-driven paracrine platelet-derived growth factor receptor alpha signaling is a key determinant of stromal cell recruitment in a model of human lung carcinoma
    Max L Tejada
    Department of Molecular Oncology, Pathology, Genentech, Inc, South San Francisco, California 94080, USA
    Clin Cancer Res 12:2676-88. 2006
    ..We propose that therapies targeting this stromal cell type may be effective in treating certain types of solid tumors...
  54. pmc Imaging tumor angiogenesis
    Kristy Red-Horse
    Genentech Inc, South San Francisco, California 94080, USA
    J Clin Invest 116:2585-7. 2006
    ....
  55. pmc Corneal avascularity is due to soluble VEGF receptor-1
    Balamurali K Ambati
    Department of Ophthalmology, Medical College of Georgia and Augusta Veterans Affairs Medical Center, Augusta, Georgia 30907, USA
    Nature 443:993-7. 2006
    ....
  56. ncbi Antiangiogenesis to treat cancer and intraocular neovascular disorders
    Farbod Shojaei
    Genentech Inc, South San Francisco, CA 94080, USA
    Lab Invest 87:227-30. 2007
    ..This brief review focuses on the progress in targeting one of the major regulators of angiogenesis, VEGF-A, and also discusses potential cellular and molecular mechanisms underlying resistance to antiangiogenic treatments...
  57. doi Napoleone Ferrara and the saga of vascular endothelial growth factor
    Domenico Ribatti
    Department of Human Anatomy and Histology, University of Bari Medical School, Bari, Italy
    Endothelium 15:1-8. 2008
    ....
  58. pmc VEGF inhibition and renal thrombotic microangiopathy
    Vera Eremina
    Samuel Lunenfeld Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada
    N Engl J Med 358:1129-36. 2008
    ..These observations provide evidence that glomerular injury in patients who are treated with bevacizumab is probably due to direct targeting of VEGF by antiangiogenic therapy...
  59. doi Effects of an anti-VEGF-A monoclonal antibody on laser-induced choroidal neovascularization in mice: optimizing methods to quantify vascular changes
    Claudio Campa
    Genentech, Inc, South San Francisco, California, USA
    Invest Ophthalmol Vis Sci 49:1178-83. 2008
    ..The purpose of this study was to evaluate different methods of detecting and quantifying experimentally induced choroidal neovascularization (CNV) and vascular changes induced on CNV by an anti-VEGF-A monoclonal antibody...
  60. pmc Role of Bv8 in neutrophil-dependent angiogenesis in a transgenic model of cancer progression
    Farbod Shojaei
    Genentech, Inc, 1 DNA Way, South San Francisco, CA 94080, USA
    Proc Natl Acad Sci U S A 105:2640-5. 2008
    ..In summary, our studies verify a role for Bv8 in the mobilization and recruitment of myeloid cells and in the induction of tumor angiogenesis in the early stages of neoplastic progression...
  61. doi Interaction between bevacizumab and murine VEGF-A: a reassessment
    Lanlan Yu
    Genentech Inc, South San Francisco, CA 94080, USA
    Invest Ophthalmol Vis Sci 49:522-7. 2008
    ..However, a recent study reported that bevacizumab is a potent inhibitor of hemangiogenesis and lymphangiogenesis in murine models. The authors sought to reassess the interaction between bevacizumab and mVEGF-A...
  62. pmc Autocrine VEGF signaling is required for vascular homeostasis
    Sunyoung Lee
    Department of Molecular, Cellular and Developmental Biology, Jonsson Comprehensive Cancer Center and Molecular Biology Institute, UCLA, Los Angeles, CA 90095, USA
    Cell 130:691-703. 2007
    ..These results reveal a cell-autonomous VEGF signaling pathway that holds significance for vascular homeostasis but is dispensable for the angiogenic cascade...
  63. ncbi Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells
    Farbod Shojaei
    Genentech, Inc, 1 DNA Way, S San Francisco, California 94080, USA
    Nat Biotechnol 25:911-20. 2007
    ..These findings indicate that, in our models, refractoriness to anti-VEGF treatment is determined by the ability of tumors to prime and recruit CD11b+Gr1+ cells...
  64. ncbi Epithelial-vascular cross talk mediated by VEGF-A and HGF signaling directs primary septae formation during distal lung morphogenesis
    Hiroaki Yamamoto
    Department of Medicine and Lung Biology Center, University of California, San Francisco, CA 94143, USA
    Dev Biol 308:44-53. 2007
    ....
  65. pmc Inhibition of VEGF-A prevents the angiogenic switch and results in increased survival of Apc+/min mice
    Nina Korsisaari
    Genentech, Inc, South San Francisco, CA 94080, USA
    Proc Natl Acad Sci U S A 104:10625-30. 2007
    ..Therefore, VEGF-A inhibition may be a previously uncharacterized strategy for the prevention of the angiogenic switch and growth in intestinal adenomas...
  66. pmc Mice expressing a humanized form of VEGF-A may provide insights into the safety and efficacy of anti-VEGF antibodies
    Hans Peter Gerber
    Genentech, Inc, 1 DNA Way, South San Francisco, CA 94080, USA
    Proc Natl Acad Sci U S A 104:3478-83. 2007
    ..However, higher-affinity antibodies were more likely to result in glomerulosclerosis during long-term treatment...
  67. ncbi Bv8 regulates myeloid-cell-dependent tumour angiogenesis
    Farbod Shojaei
    Genentech Inc, 1 DNA Way, South San Francisco, California 94080, USA
    Nature 450:825-31. 2007
    ..Thus, Bv8 modulates mobilization of CD11b+Gr1+ cells from the bone marrow during tumour development and also promotes angiogenesis locally...
  68. ncbi Redundant roles of VEGF-B and PlGF during selective VEGF-A blockade in mice
    Ajay K Malik
    Department of Pathology, Genentech, South San Francisco, CA 94080, USA
    Blood 107:550-7. 2006
    ..The absence of compensatory VEGFR-1 signaling by VEGF-B and PlGF may have important implications for the development of anticancer strategies targeting the VEGF ligand/receptor system...
  69. ncbi HIF-1alpha is essential for myeloid cell-mediated inflammation
    Thorsten Cramer
    Molecular Biology Section, Division of Biological Sciences, School of Medicine, University of California, San Diego, La Jolla, CA 92093, USA
    Cell 112:645-57. 2003
    ..This role for HIF-1alpha demonstrates its direct regulation of survival and function in the inflammatory microenvironment...
  70. pmc The endocrine-gland-derived VEGF homologue Bv8 promotes angiogenesis in the testis: Localization of Bv8 receptors to endothelial cells
    Jennifer LeCouter
    Department of Molecular Oncology, Genentech, Inc, South San Francisco, CA 94080, USA
    Proc Natl Acad Sci U S A 100:2685-90. 2003
    ..The testis exhibits relatively high turnover of endothelial cells. Therefore, Bv8 and EG-VEGF, along with other factors such as VEGF-A, may maintain the integrity and also regulate proliferation of the blood vessels in the testis...
  71. ncbi Angiogenesis-independent endothelial protection of liver: role of VEGFR-1
    Jennifer LeCouter
    Departments of Molecular Oncology, Protein Engineering, and Pathology, Genentech Inc, 1 DNA Way, South San Francisco, CA 94080, USA
    Science 299:890-3. 2003
    ..Thus, VEGFR-1 agonists may have therapeutic potential for preservation of organ function in certain liver disorders...
  72. ncbi The role of VEGF in normal and neoplastic hematopoiesis
    Hans Peter Gerber
    Department of Molecular Oncology, Genentech Inc, 1 DNA Way, South San Francisco, CA 94080, USA
    J Mol Med (Berl) 81:20-31. 2003
    ....
  73. ncbi Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications
    Napoleone Ferrara
    Genentech, Inc, 1 DNA Way MS 40, South San Francisco, CA 94080, USA
    Semin Oncol 29:10-4. 2002
    ..Clinical efficacy of antiangiogenic therapy with bevacizumab is being evaluated in several phase 3 trials in various types of cancer, as well as in patients with age-related macular degeneration...
  74. pmc Vascular endothelial growth factor immunoneutralization plus Paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer
    Limin Hu
    Center for Reproductive Sciences, University of California at San Francisco 94143, USA
    Am J Pathol 161:1917-24. 2002
    ..Thus, combination therapy with inhibitors of VEGF plus paclitaxel may be an effective way to markedly reduce tumor growth and ascites in ovarian carcinoma...
  75. ncbi Endocrine gland-derived VEGF and the emerging hypothesis of organ-specific regulation of angiogenesis
    Jennifer LeCouter
    Department of Molecular Oncology, Genentech, Inc, South San Francisco, California, USA
    Nat Med 8:913-7. 2002
    ..Endocrine gland-derived VEGF represents the first example of a tissue-specific angiogenic factor, likely to be followed by others...
  76. pmc Vascular endothelial growth factor stimulates bone repair by promoting angiogenesis and bone turnover
    John Street
    Department of Academic Surgery, National University of Ireland, University College Cork, Cork, Ireland
    Proc Natl Acad Sci U S A 99:9656-61. 2002
    ....
  77. ncbi VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism
    Hans Peter Gerber
    Department of Molecular Oncology, Genentech, Inc, 1 DNA Way, South San Francisco, California 94080, USA
    Nature 417:954-8. 2002
    ..Not only ligands selective for VEGF and VEGFR-2 but also VEGFR-1 agonists rescued survival and repopulation of VEGF-deficient HSCs, revealing a function for VEGFR-1 signalling during haematopoiesis...
  78. ncbi VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis
    Masahiro Inoue
    Department of Biochemistry and Biophysics, Diabetes and Comprehensive Cancer Centers, University of California at San Francisco, San Francisco, CA 94143, USA
    Cancer Cell 1:193-202. 2002
    ..Thus, VEGF-A is crucial for angiogenesis in a prototypical model of carcinogenesis, whose loss is not readily compensated...
  79. ncbi ANGPTL3 stimulates endothelial cell adhesion and migration via integrin alpha vbeta 3 and induces blood vessel formation in vivo
    Gieri Camenisch
    Department of Molecular Oncology, Genentech, Inc, South San Francisco, California 94080, USA
    J Biol Chem 277:17281-90. 2002
    ..Taken together, our data demonstrate that ANGPTL3 is the first member of the angiopoietin-like family of secreted factors binding to integrin alpha(v)beta(3) and suggest a possible role in the regulation of angiogenesis...
  80. ncbi Characterization of endocrine gland-derived vascular endothelial growth factor signaling in adrenal cortex capillary endothelial cells
    Rui Lin
    Department of Molecular Oncology, Genentech Inc, South San Francisco, California 94080, USA
    J Biol Chem 277:8724-9. 2002
    ....
  81. ncbi Vascular endothelial growth factor (VEGF) receptor-2 signaling mediates VEGF-C(deltaNdeltaC)- and VEGF-A-induced angiogenesis in vitro
    Jean Christophe Tille
    Department of Cell Biology and Morphology, University Medical Center, Geneva, Switzerland
    Exp Cell Res 285:286-98. 2003
    ..Taken together, these findings point to the central role of VEGFR-2 in the angiogenic signaling pathways induced by VEGF-C(deltaNdeltaC) and VEGF-A...
  82. ncbi Mouse endocrine gland-derived vascular endothelial growth factor: a distinct expression pattern from its human ortholog suggests different roles as a regulator of organ-specific angiogenesis
    Jennifer LeCouter
    Department of Molecular Oncology, Genentech Inc, South San Francisco, California 94080, USA
    Endocrinology 144:2606-16. 2003
    ..We propose that mouse EG-VEGF, like human EG-VEGF, plays a role in regulating the phenotype and growth properties of endothelial cells within distinct capillary beds...
  83. pmc Differential expression of the angiogenic factor genes vascular endothelial growth factor (VEGF) and endocrine gland-derived VEGF in normal and polycystic human ovaries
    Napoleone Ferrara
    Department of Molecular Oncology, Genentech Incorporated, South San Francisco, California 94080, USA
    Am J Pathol 162:1881-93. 2003
    ....
  84. ncbi Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies
    Hans Peter Gerber
    Departments of Molecular Oncology, Genentech Inc, 1 DNA Way, South San Francisco, CA 94080, USA
    Cancer Res 65:671-80. 2005
    ..Finally, safety pharmacology studies with bevacizumab in cynomolgus monkeys showed that this agent is generally well tolerated with no unexpected adverse events...
  85. pmc Bv8 and endocrine gland-derived vascular endothelial growth factor stimulate hematopoiesis and hematopoietic cell mobilization
    Jennifer LeCouter
    Department of Physiology, Genentech, Inc, South San Francisco, CA 94080, USA
    Proc Natl Acad Sci U S A 101:16813-8. 2004
    ..Bv8 potentially modulates growth, survival, and function of cells of the innate and adaptive immune systems, possibly through autocrine or paracrine signaling mechanisms...
  86. ncbi Loss of HIF-1alpha in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesis
    Nan Tang
    Molecular Biology Section, Division of Biological Sciences, University of California, San Diego, San Diego, California 92093, USA
    Cancer Cell 6:485-95. 2004
    ..We thus show that a HIF-1alpha-driven, VEGF-mediated autocrine loop in EC is an essential component of solid tumor angiogenesis...
  87. ncbi Angiogenesis-dependent and independent phases of intimal hyperplasia
    Rohit Khurana
    Centre for Cardiovascular Biology and Medicine, Department of Medicine, University College, London, UK
    Circulation 110:2436-43. 2004
    ..Because percutaneous coronary interventions result in induction of periadventitial angiogenesis, we analyzed the role of this process in neointima formation...
  88. ncbi Neutralizing VEGF bioactivity with a soluble chimeric VEGF-receptor protein flt(1-3)IgG inhibits testosterone-stimulated prostate growth in castrated mice
    Ingela Franck Lissbrant
    Department of Medical Biosciences, Pathology, Umea University, Umea, Sweden
    Prostate 58:57-65. 2004
    ..These observations suggest that testosterone-stimulated prostate growth could be angiogenesis dependent, and that VEGF could play a central role in this process...
  89. ncbi Decrease in tumor apparent permeability-surface area product to a MRI macromolecular contrast medium following angiogenesis inhibition with correlations to cytotoxic drug accumulation
    Heike E Daldrup-Link
    Center for Pharmaceutical and Molecular Imaging, Department of Radiology, University of California, San Francisco, California 94143 0628, USA
    Microcirculation 11:387-96. 2004
    ....
  90. pmc VEGF-null cells require PDGFR alpha signaling-mediated stromal fibroblast recruitment for tumorigenesis
    Jianying Dong
    Department of Molecular Oncology, Genentech Inc, South San Francisco, CA 94080, USA
    EMBO J 23:2800-10. 2004
    ..Thus, PDGFR alpha signaling is required for the recruitment of VEGF-producing stromal fibroblasts for tumor angiogenesis and growth. Our findings highlight a novel aspect of PDGFR alpha signaling in tumorigenesis...
  91. ncbi Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
    Herbert Hurwitz
    Duke University, Durham, NC, USA
    N Engl J Med 350:2335-42. 2004
    ..Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, has shown promising preclinical and clinical activity against metastatic colorectal cancer, particularly in combination with chemotherapy...
  92. ncbi VEGFA is necessary for chondrocyte survival during bone development
    Elazar Zelzer
    Department of Cell Biology, Harvard Medical School, Boston, MA 02115, USA
    Development 131:2161-71. 2004
    ....
  93. ncbi Down syndrome critical region protein 1 (DSCR1), a novel VEGF target gene that regulates expression of inflammatory markers on activated endothelial cells
    Boris A Hesser
    Department of Molecular Oncology, Genentech, South San Francisco, CA 94080, USA
    Blood 104:149-58. 2004
    ....
  94. ncbi EG-VEGF and Bv8. a novel family of tissue-selective mediators of angiogenesis, endothelial phenotype, and function
    Jennifer LeCouter
    Department of Molecular Oncology, Genentech Inc, 1 DNA Way, South San Francisco, CA 94080, USA
    Trends Cardiovasc Med 13:276-82. 2003
    ..The potential advantage of tissue-specific angiogenic therapeutics may be the reduction of systemic side effects. Additionally, these peptides or their receptors may be attractive targets for inhibition in several disorders...
  95. ncbi The hypoxic response of tumors is dependent on their microenvironment
    Barbara Blouw
    Molecular Biology Section, Division of Biological Sciences, University of California at San Diego, Pacific Hall Room 1212, MC 0366, 9500 Gilman Drive, La Jolla, CA 92093, USA
    Cancer Cell 4:133-46. 2003
    ..These results demonstrate that HIF-1alpha has differential roles in tumor progression, which are greatly dependent on the extant microenvironment of the tumor...
  96. ncbi VEGF regulates remodeling during permanent anatomic closure of the ductus arteriosus
    Ronald I Clyman
    Cardiovascular Research Institute, University of California, San Francisco, California 94143 0544, USA
    Am J Physiol Regul Integr Comp Physiol 282:R199-206. 2002
    ..05) increase in vasa vasorum ingrowth and neointima formation. We conclude that VEGF plays an important role in the formation of neointimal mounds and vasa vasorum ingrowth during permanent ductus closure...

Research Grants1

  1. Angiogenesis:Novel Basic Science Insight & Human Therapy
    Napoleone Ferrara; Fiscal Year: 2004
    ..abstract_text> ..